 |
BioWorld-International-2004-07-07
Italian Biotech Start-Up Program Receives International Assistance
Cyclacel Prepares For Dual IPO: Nasdaq, London Stock Exchange
LONDON - Cyclacel Group plc announced a dual listing on Nasdaq and the London Stock Exchange seeking £26.6 million (US$48 million) to charge development of the lead compound from its orally available cyclin dependent kinase inhibitor program in a bid to be first to market. (BioWorld International)